Literature DB >> 16774845

Leptin enhances in vitro secretion of IgG antiplatelet antibodies by splenocytes and peripheral blood mononuclear cells from patients with chronic idiopathic thrombocytopenic purpura.

He Ren1, Hui Zhao, Tingting Wang, Yanhui Yang, Zhibo Han, Bin Liu, Zida Wu, Jie Tao, Bin Zhou, Lei Zhang, Renchi Yang, Zhong Chao Han.   

Abstract

Chronic idiopathic thrombocytopenic purpura (ITP) is an organ-specific autoimmune disease characterized by the production of antibodies against antigens on the membranes of platelets, resulting in enhanced destruction of the platelets by macrophages. Leptin, a cytokine-like hormone, plays a role in the pathogenesis of several autoimmune diseases. In this study, we observed significantly increased plasma leptin levels combined with decreased soluble leptin receptor (sOB-R) levels in 18 chronic ITP patients compared with 14 controls. We also demonstrated significantly elevated mRNA expression of long form leptin receptor (Ob-Rb) on peripheral blood mononuclear cells (PBMCs) from chronic ITP patients. Treatment with recombinant leptin or serum with high leptin levels enhanced in vitro secretion of IgG antiplatelet antibodies by splenocytes and PBMCs from patients with chronic ITP. After depletion of CD4(+) T cells from splenocytes, leptin lost this function. Further studies showed that leptin could increase platelet reactive T cells. These findings suggest that leptin may be involved in the pathogenesis of chronic ITP and might offer a potential target for the treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16774845     DOI: 10.1016/j.clim.2006.04.573

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  1 in total

1.  Prostate-specific membrane antigen as a marker of pancreatic cancer cells.

Authors:  He Ren; Huan Zhang; Xiuchao Wang; Junxiu Liu; Zhanna Yuan; Jihui Hao
Journal:  Med Oncol       Date:  2014-01-30       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.